Hepatitis C Virus

Hepatitis C interferon-ribavirin therapy associated with hemoglobin decline in diabetes

Published in Hepatitis Weekly, October 16th, 2006

A study from the United States has reported on the decline in hemoglobin (Hb) A1c (A1c) values in diabetic patients receiving interferon-alpha (IFN) and ribavirin (RBV) for chronic hepatitis C.

"Hb A1c levels are lower during haemolysis because of the shorter exposure of Hb to plasma glucose. RBV used in combination with IFN for chronic hepatitis C causes reversible haemolytic anaemia.

"This study examined the extent to which RBV treatment influences A1c levels in diabetic patients. A retrospective analysis identified 32 diabetic patients who underwent hepatitis C treatment with IFN and RBV," wrote P.D. Greenberg and colleagues, Bronx Veterans...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-10-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry